Biotech drugs - revenues
This statistic shows the revenues of selected key biotech drugs in 2010. In that year, the revenue of biotech drug Rituxan was at 6.6 billion U.S. dollars.
Revenues of selected key biotech drugs in 2010 (in billion U.S. dollars)
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 5 people
$959 USD
per month, billed annually
1
- Free + Premium Statistics
- Reports
- Market Insights
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Pharmaceutical market worldwide
Overview
5
- Premium Statistic Pharmaceutical market: worldwide revenue 2001-2023
- Premium Statistic World pharmaceutical sales 2020-2023 by region
- Premium Statistic World pharmaceutical market distribution by submarket 2014-2023
- Premium Statistic Revenues of top 10 global pharmaceutical markets 2023
- Basic Statistic Top pharmaceutical products by sales worldwide 2023
Segments
7
- Premium Statistic Top therapy classes by spending global market 2027 forecast
- Basic Statistic Global pharmaceutical revenue by technology 2012-2026
- Basic Statistic Worldwide Rx drug sales excluding generics and orphan drugs 2012-2026
- Basic Statistic Projection of global revenue for orphan prescription drugs 2016-2028
- Basic Statistic Worldwide generic prescription drug sales 2012-2026
- Premium Statistic Revenue of the OTC pharmaceuticals industry worldwide 2018-2029
- Premium Statistic Global oncology spending 2013-2024
Companies
8
- Premium Statistic Top 50 pharmaceutical companies - Rx sales and R&D spending 2023
- Premium Statistic Top 10 biotech and pharmaceutical companies based on market cap 2024
- Basic Statistic Global pharma market share by top companies 2022
- Premium Statistic Pfizer's total revenue 2006-2023
- Premium Statistic Roche Group's total sales 2006-2023
- Premium Statistic Johnson & Johnson's total sales 2005-2023
- Basic Statistic AbbVie's revenue 2010-2023
- Basic Statistic Projected top pharmaceutical companies based on new sales 2023
R&D, patents, new products
8
- Premium Statistic Total global pharmaceutical R&D spending 2014-2030
- Basic Statistic Global top pharmaceutical companies based on R&D spending 2026
- Premium Statistic Patent expiration risk for total worldwide global Rx drug revenue 2024-2030
- Basic Statistic Worldwide Rx drug revenue - market at risk from patent expiration 2024-2030
- Premium Statistic Pharmaceutical industry - number of new substances 1998-2023
- Basic Statistic Pharma companies worldwide with active R&D pipelines 2001-2024
- Premium Statistic Number of novel drugs approved annually by CDER 2008-2023
- Basic Statistic Projected most valuable R&D projects based on net present value 2023
Outlook
7
- Premium Statistic World pharmaceutical sales by region forecast 2027
- Premium Statistic Global spending on medicines 2010-2027
- Premium Statistic CAGR by product type in pharmaceutical markets forecast 2023-2027
- Basic Statistic Country comparison in spending on medicine 2026
- Basic Statistic Top global biopharma drugs by lifetime sales up to 2028
- Basic Statistic Sales forecast of top pharmaceutical companies worldwide 2028
- Premium Statistic Sales forecast of top selling drugs worldwide 2028
Focus: COVID-19 response
6
- Basic Statistic Biotechs: duration of COVID-19 response compared to previous health threats 2003-2019
- Premium Statistic BARDA funding for the development of COVID-19 vaccines in the U.S. 2021
- Premium Statistic Shareholdings at select COVID-19 vaccine companies by investor 2021
- Premium Statistic Top companies by COVID-19 treatment vaccines in development June 2022
- Basic Statistic Comparison of select COVID-19 vaccines 2022, by efficacy
- Basic Statistic Distribution of COVID-19 vaccines worldwide by mechanism and phase 2022
Further related statistics
9
- M&A capacities - changes for the global pharma industry 2008-2015
- Merck & Co total assets 2019 to 2023
- Merck & Co cash dividends declared 2006-2023
- Merck & Co - expenditure on research and development 2006-2023
- Johnson & Johnson's number of employees 2004-2023
- Cvs Health total assets 2019 to 2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Expenditure worldwide on diabetes by market 2013-2018
- Global pharmaceutical pipeline by therapy area 2013-2017
Further Content: You might find this interesting as well
Statistics
- M&A capacities - changes for the global pharma industry 2008-2015
- Merck & Co total assets 2019 to 2023
- Merck & Co cash dividends declared 2006-2023
- Merck & Co - expenditure on research and development 2006-2023
- Johnson & Johnson's number of employees 2004-2023
- Cvs Health total assets 2019 to 2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Expenditure worldwide on diabetes by market 2013-2018
- Global pharmaceutical pipeline by therapy area 2013-2017
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 5 people
$959 USD
per month, billed annually
1
- Free + Premium Statistics
- Reports
- Market Insights
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Handelsblatt. (February 9, 2011). Revenues of selected key biotech drugs in 2010 (in billion U.S. dollars) [Graph]. In Statista. Retrieved November 01, 2024, from https://www.statista.com/statistics/271568/revenues-of-selected-key-biotech-drugs-2010/
Handelsblatt. "Revenues of selected key biotech drugs in 2010 (in billion U.S. dollars)." Chart. February 9, 2011. Statista. Accessed November 01, 2024. https://www.statista.com/statistics/271568/revenues-of-selected-key-biotech-drugs-2010/
Handelsblatt. (2011). Revenues of selected key biotech drugs in 2010 (in billion U.S. dollars). Statista. Statista Inc.. Accessed: November 01, 2024. https://www.statista.com/statistics/271568/revenues-of-selected-key-biotech-drugs-2010/
Handelsblatt. "Revenues of Selected Key Biotech Drugs in 2010 (in Billion U.S. Dollars)." Statista, Statista Inc., 9 Feb 2011, https://www.statista.com/statistics/271568/revenues-of-selected-key-biotech-drugs-2010/
Handelsblatt, Revenues of selected key biotech drugs in 2010 (in billion U.S. dollars) Statista, https://www.statista.com/statistics/271568/revenues-of-selected-key-biotech-drugs-2010/ (last visited November 01, 2024)
Revenues of selected key biotech drugs in 2010 (in billion U.S. dollars) [Graph], Handelsblatt, February 9, 2011. [Online]. Available: https://www.statista.com/statistics/271568/revenues-of-selected-key-biotech-drugs-2010/